ROVI announces the marketing agreement of Neparvis in Spain


No votes yet
 
Related
ROVI informs on the evaluation process to obtain marketing authorisation for Risvan® The United States Food and Drug Administration (...
1 min
28/07/2023
ROVI ACHIEVED STABLE TOTAL REVENUE OF 381.0 MILLION EUROS IN THE FIRST POST-PANDEMIC HALF YEAR Operating revenue remained stable,...
4 min
26/07/2023
ROVI REACHED 201.9 MILLION EUROS OF REVENUE IN THE FIRST POST-PANDEMIC QUARTER Operating revenue decreased by 2% to 201.6 million...
3 min
10/05/2023